(+) Acorda Therapeutics ( ACOR ), which was up by more than 13% after the US Food and Drug Administration approved Inbrija for the intermittent treatment of OFF episodes in people with Parkinson’s disease treated with carbidopa/levodopa.
In other sector news:
(+) ChromaDex ( CDXC ) was down more than 1%. In after hours Dec. 20 the company unveiled a license and supply agreement with Nestle Health Science providing the latter with exclusive right to CDXC’s nicotinamide riboside ingredient TRU NIAGEN dietary supplement in its branded medical nutrition.
(=) India-based drug maker Dr. Reddy’s Laboratories Ltd ( RDY ) was flat after it launched the sale of aspirin and extended-release Dipyridamole capsules, a generic version of Aggrenox, in the United States.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
Zeen is a next generation WordPress theme. It’s powerful, beautifully designed and comes with everything you need to engage your visitors and increase conversions.
Go to Appearance > Customize > Subscribe Pop-up to set this up.
Wealth Empire Newsletter
Register now for free updates and alerts
Note: I have the ability to revoke this permission at any time and ask for the removal of my personal data collected by contacting us or simply clicking Unsubscribe.